Entrada Therapeutics, Inc. (TRDA) stock
TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.17−0.27 (-4.96%)
Close on Nov 12, 2026Market cap $201.30MP/E –Yield –
Entrada Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Entrada Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -4303.8%. For fiscal 2025 it was -621.1%, against 22.3% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -621.1% | −643.4 |
| FY2024 | Dec 31, 2024 | 22.3% | +24.8 |
| FY2023 | Dec 31, 2023 | -2.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -4606.5% | −1691.3 |
| Q2 FY2026 | Jun 30, 2026 | -5007.0% | −2604.5 |
| Q1 FY2026 | Mar 31, 2026 | -4834.6% | −4728.6 |
| Q4 FY2025 | Dec 31, 2025 | -3249.3% | −3233.6 |
| Q3 FY2025 | Sep 30, 2025 | -2915.2% | −2804.5 |
| Q2 FY2025 | Jun 30, 2025 | -2402.5% | −2458.9 |
| Q1 FY2025 | Mar 31, 2025 | -106.0% | −141.7 |
| Q4 FY2024 | Dec 31, 2024 | -15.7% | −27.4 |
| Q3 FY2024 | Sep 30, 2024 | -110.7% | −142.7 |
| Q2 FY2024 | Jun 30, 2024 | 56.4% | +146.1 |
| Q1 FY2024 | Mar 31, 2024 | 35.7% | +58.6 |
| Q4 FY2023 | Dec 31, 2023 | 11.7% | – |
| Q3 FY2023 | Sep 30, 2023 | 32.0% | – |
| Q2 FY2023 | Jun 30, 2023 | -89.7% | – |
| Q1 FY2023 | Mar 31, 2023 | -22.9% | – |
See a number that looks wrong?